Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Shaping the future of safer innovative drugs in Europe

Nature Biotechnology volume 29, pages 789–790 (2011)Cite this article

Subjects

To the Editor:

An Editorial entitled “Members need only apply” published in the July issue1 expressed concerns about the input of small- to medium-sized enterprises (SMEs) into the agenda of the Innovative Medicine Initiative (IMI) Joint Undertaking. The editorial argued that the SMEs currently participating in IMI projects do not represent the whole spectrum of companies that make up the innovative biotech space in Europe. We would like to address these criticisms in the context of the eTOX consortium, one of the projects funded following the IMI's first call for proposals in 2008 and specifically singled out for comment in the Editorial.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Anonymous. Nat. Biotechnol. 29, 551 (2011).

  2. Richard, A.M. Chem. Res. Toxicol. 19, 1257–1262 (2006).

    Article  CAS  Google Scholar 

  3. Nigsch, F., Macaluso, N.J.M., Mitchell, J.B.O. & Zmuidinavicius, D. Expert Opin. Drug Metab. Toxicol. 5, 1–14 (2009).

    Article  CAS  Google Scholar 

  4. Merlot, C. Drug Discov. Today 15, 16–22 (2010).

    Article  CAS  Google Scholar 

  5. Rusyn, I. & Daston, G.P. Environ. Health Perspect. 118, 1047–1050 (2010).

    Article  Google Scholar 

  6. Gasteiger, J. (ed.). Handbook of Chemoinformatics—From Data to Knowledge (Wiley-VCH: Weinheim, 2003).

    Book  Google Scholar 

  7. Gasteiger, J. J. Med. Chem. 49, 6429–6434 (2006).

    Article  CAS  Google Scholar 

  8. Vaz, R.J. et al. Expert Opin. Drug Metab. Toxicol. 6, 851–861 (2010).

    Article  CAS  Google Scholar 

  9. Bonn, B., Leandersson, C., Fontaine, F. & Zamora, I. Rapid Commun. Mass Spectrom. 24, 3127–3138 (2010).

    Article  CAS  Google Scholar 

  10. Wolber, G. & Langer, T. J. Chem. Inf. Model. 45, 160–169 (2005).

    Article  CAS  Google Scholar 

  11. Wolber, G., Domhofer, A. & Langer, T. J. Comput. Aided Mol. Des. 20, 773–788 (2006).

    Article  CAS  Google Scholar 

  12. Mestres, J., Gregori-Puigjané, E., Valverde, S. & Solé, R.V. Nat. Biotechnol. 26, 983–984 (2008).

    Article  CAS  Google Scholar 

  13. Garcia-Serna, R. & Mestres, J. Expert Opin. Drug Metab. Toxicol. 6, 1253–1263 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chemotargets, IMIM-Hospital del Mar,

    Jordi Mestres

  2. University Pompeu Fabra, Barcelona, Catalonia, Spain

    Jordi Mestres

  3. Inte:Ligand, Vienna, Austria

    Sharon D Bryant

  4. Lead Molecular Design, Sant Cugat del Vallès, Spain

    Ismael Zamora

  5. Molecular Networks, Erlangen, Germany

    Johann Gasteiger

Authors
  1. Jordi Mestres
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sharon D Bryant
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ismael Zamora
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Johann Gasteiger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jordi Mestres.

Ethics declarations

Competing interests

J.M. is the president of Chemotargets, S.D.B. is the CEO of Inte:Ligand, I.E. is the CEO of Lead Molecular Design and J.G. is the president of Molecular Networks.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mestres, J., Bryant, S., Zamora, I. et al. Shaping the future of safer innovative drugs in Europe. Nat Biotechnol 29, 789–790 (2011). https://doi.org/10.1038/nbt.1973

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.1973

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research